Terms: = Liver cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Diagnosis
5 results:
1. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract] [Full Text] [Related]
2. Centrosome amplification-related signature correlated with immune microenvironment and treatment response predicts prognosis and improves diagnosis of hepatocellular carcinoma by integrating machine learning and single-cell analyses.
Liu Y; He M; Ke X; Chen Y; Zhu J; Tan Z; Chen J
Hepatol Int; 2024 Feb; 18(1):108-130. PubMed ID: 37154991
[TBL] [Abstract] [Full Text] [Related]
3. Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma.
Wang T; Liu M; Zheng SJ; Bian DD; Zhang JY; Yao J; Zheng QF; Shi AM; Li WH; Li L; Chen Y; Wang JH; Duan ZP; Dong L
World J Gastroenterol; 2017 May; 23(19):3496-3504. PubMed ID: 28596685
[TBL] [Abstract] [Full Text] [Related]
4. Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma.
Liu M; Varela-Ramirez A; Li J; Dai L; Aguilera RJ; Zhang JY
Oncol Rep; 2015 May; 33(5):2245-52. PubMed ID: 25779011
[TBL] [Abstract] [Full Text] [Related]
5. Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan.
Ohira H; Abe K; Takahashi A; Zeniya M; Ichida T
J Gastroenterol; 2013 Jan; 48(1):109-14. PubMed ID: 22688407
[TBL] [Abstract] [Full Text] [Related]